值得注意的是，据香港联交所披露易公布的数据，创始人、执行董事、董事会主席兼首席执行官俞德超在9月30日和10月2日合计减持信达生物325万股，总金额约1.52亿港元。减持后，俞德超所持股份占比由7.90%降至7.70%，持股数降为约1.2597亿股。此外，9月11日，摩根大通减持信达生物1553.61万股普通股股份，价值约6.69亿港元。Innovent Bio (01801) fell another 10% intraday, as of the time of writing, down 4.92% to HKD 47.35, with a turnover of 1.627 billion Hong Kong dollars.
According to the Wise News & Finance app, Innovent Bio (01801) fell another 10% intraday, down 4.92% to HKD 47.35 as of the time of writing, with a turnover of 1.627 billion Hong Kong dollars.
On the news front, Innovent Bio recently signed a cooperation agreement with Beijing Aosaikang Pharmaceutical. Both parties will reach an exclusive commercial cooperation on the third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeted drug "Irenesatini Tablets" (commodity name: Aoyixin). It is reported that the National Medical Products Administration is currently reviewing and approving two indications for new drug applications for Irenesatini Tablets. Yu Dechao, the founder, chairman, and CEO of Innovent Bio Group, stated that the cooperation on Aoyixin with Beijing Aosaikang is expected to provide an innovative targeted drug for many EGFR mutation lung cancer patients, while further enhancing Innovent Bio's leading position in the field of cancer treatment.
It is worth noting that according to data disclosed by the Hong Kong Stock Exchange, Yu Dechao, the founder, executive director, chairman, and CEO, collectively reduced his shareholding in Innovent Bio by 3.25 million shares on September 30 and October 2, with a total amount of approximately 0.152 billion Hong Kong dollars. After the reduction, Yu Dechao's shareholding percentage decreased from 7.90% to 7.70%, and the number of shares held decreased to approximately 0.12597 billion shares. In addition, on September 11, JPMorgan reduced its shareholding in Innovent Bio by 15.5361 million ordinary shares, with a value of approximately 0.669 billion Hong Kong dollars.
